Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Neuropharmacology. 2018 Sep 7;141:260–271. doi: 10.1016/j.neuropharm.2018.09.005

Figure 7. The effect of MK-801 and MMP-2200 on L-DOPA-induced AIMs.

Figure 7.

The noncompetitive NMDA receptor antagonist MK-801 has previously been shown to have potent anti- dyskinetic activity only at a dose that also induces parkinsonism. Time-course plots are shown: (A) MK-801 (0.3 mg/kg) reduces LAO AIMs by > 90%. (D) MK-801 (0.3 mg/kg) induces proparkinsonian ipsiversive rotations, indicative of an induced parkinsonian state. Coadministration of 10 mg/kg MMP-2200 (B and E) and 20 mg/kg MMP-2200 (C and F) with MK-801 have no impact on the anti-dyskinetic efficacy of MK-801 on LAO AIMs (B and C), while both L-DOPA-induced contraversive rotations and MK-801-induced ipsiversive rotations are completely abolished (E and F); mean AIMs scores ± SEM; n = 9–10; * p < 0.05.